CD70 and neoplasm: used azacitidine to increase antigen density of CD7 in tumor cells and designed a CD8 hinger and transmembrane-modified CD27-based CD70 CAR to mitigate cleavage of the extracellular portion of CD27, altogether could enhance avidity and expansion of CD70 CAR-T cells and lead to more potent activity in vivo (153).